Programs & Groups

Working in close collaboration with multiple VHIO research groups, the Data Engineering for Research Unit focuses on the standardization, integration, and digitization of biomedical data. In addition to actively contributing to several research projects, the Unit develops and maintains robust infrastructure and environments that support institutional data storage, accessibility, interoperability, and governance.

The Unit manages a wide range of data types, including clinical, omics, imaging, and other biomedical datasets, aiming to maximize their usability and research value while providing investigators with appropriate tools and support. The team also contributes to the definition and implementation of Data Management Plans (DMPs), ensuring compliance with institutional and regulatory data management requirements throughout the data lifecycle.

Through the design and implementation of ETL (Extract, Transform, Load) pipelines, the development of structured and interoperable databases, the integration of heterogeneous data sources, and the creation and maintenance of specialized software solutions, the Unit provides a reliable framework that enables researchers to efficiently generate, manage, and exploit research data.

The Unit is actively advancing Artificial Intelligence (AI)-driven initiatives, including the development of clinical trial matching tools to support patient recruitment and the implementation of large language model (LLM) approaches for the structuring and extraction of information from unstructured clinical notes. These efforts aim to enhance data usability, accelerate clinical research workflows, and contribute to precision oncology initiatives.

**Figure:** Overview of the Data Engineering for Research Unit, integrating data infrastructure, governance, and AI solutions to support translational research.

Advance institutional clinical data standardization through expansion of the OMOP common data model and FAIR-aligned data governance practices.
Consolidate and expand the VHIO Data Lake (VHIO-Lake) as a secure, interoperable environment integrating clinical, molecular, imaging, pharmacy, and clinical trial datasets.
Strengthen data interoperability across institutional systems through scalable ETL pipelines, structured databases, and harmonized digital platforms.
Enhance advanced data exploration and visualization through integrative tools (e.g., cBioPortal, OMERO) to support translational and precision oncology research.
Expand AI-driven initiatives, including LLM-based structuring of clinical notes and intelligent tools for clinical trial patient matching.
Develop tailored digital solutions to support research data capture, patient tracking, and project-specific institutional needs.

Deployment of VHIO-Lake, integrating heterogeneous clinical, molecular, pharmacy, and trial datasets within a unified and interoperable architecture.
Expansion of OMOP-based institutional clinical database, enabling standardized, research-ready data access across multiple projects.
Institutional rollout of OMERO and expansion of cBioPortal, strengthening digital pathology management and clinical-genomic integration.
Automation of scalable ETL pipelines, improving efficiency, reproducibility, and secure data flows for research and analytics.
Institution-wide data ecosystem assessment, defining a strategic roadmap for enhanced governance, infrastructure, and sustainable data development.

Scale up and fully operationalize the VHIO Data Lake, further integrating clinical, pharmacy, trial, molecular, and imaging datasets across projects.
Expand and consolidate the use of institutional platforms, including OMOP databases, cBioPortal, and OMERO, to maximize interoperability and research utility.
Strengthen collaboration with Vall d’Hebron University Hospital and other partners to optimize automated data extraction, harmonization, and ETL pipelines.
Develop and deploy advanced AI-driven tools to support clinical trial patient matching, structured extraction from unstructured clinical notes, and predictive analytics for research projects.
Implement a comprehensive institutional Data Catalog and metadata framework to map data assets, support FAIR principles, and identify unmet data needs.
Enhance digital solutions for patient and sample tracking, clinical study management, and integration with ongoing research projects.
Explore new approaches for multi-omics integration, visualization, and analysis to support translational research and precision oncology initiatives.

Projects

SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applications. Funded by the European Commission.  01/09/2024-31/08/2029. PI: Rodrigo Dienstmann.
Cancer Core Europe (CCE). Founded in 2014, this consortium comprises seven leading European comprehensive cancer centers, including VHIO, to accelerate the development of innovative cancer therapies through close collaboration in translational and clinical research.
The EU-funded CCE Building Data Rich Clinical Trials (CCE_DART) is an innovative project dedicated to deliver novel methods for the design and implementation of newer, more efficient and effective clinical trials in oncology.
Historia clínica Inteligente: Transformando Notas Clínicas en Datos Estructurado.
EU-funded AI4Lungs project: AI-Based Personalised Care for Respiratory Disease using Multi-Modal Data in Patient Stratification.
American Association for Cancer Research (AACR) Project GENIE® (Genomics Evidence Neoplasia Information Exchange).
PROLoNg: Phase III randomized study evaluating Pembrolizumab combined with radiotherapy for oligometastatic squamous cell carcinoma of the head and neck.
REDEcon: Strategic Advisory Network on Cancer Policies (Red ECON), aims to bridge the scientific-health ecosystem and Spanish authorities by developing national data frameworks, R&D&I strategies, and recommendations to optimize patient care and research integration.
EUnetCCC: European Network of Cancer Centres (EUnetCCC), aiming to foster collaboration among leading cancer centers across Europe to harmonize data sharing, promote best practices, and support multicenter research initiatives in oncology.

Data Science Program

Bioinformatics Unit

VHIO’s Bioinformatics Unit (VHIOinformatics) provides research groups with cutting-edge computational resources for the analysis of cancer-related omics data. We support VHIO investigators through the implementation of state-of-the-art bioinformatic pipelines and the processing of multi-omics datasets.

Collaborating with researchers across multiple projects, we participate in different stages of research from conception or experimental design through to bioinformatic data analysis and final publication, with particular focus on visualization and functional interpretation. In 2025 we conducted fifty-eight data analyses in collaboration with twenty-five VHIO research groups. The study set comprised mainly transcriptomics and genomics data, but it was enriched by shotgun metagenomics projects to explore the tumor micro‑environment. We also performed reassessment of several publicly available datasets to gain insights into the development and spread of cancer. With the recent onboarding of single‑cell technologies and expertise, we are now analyzing several transcriptomic and multi-omics single-cell experiments.

Following the FAIR Guiding Principles for scientific data management, we have developed a guide for uploading data to public repositories, with a particular emphasis on the EGA, our reference repository for controlled-access human data. Several of our internal datasets—already featured in recent publications—have been deposited in publicly accessible repositories to support open science and data reuse.

Our computational procedures are based on open-source software developed in a secure and reproducible environment. Available to bioinformaticians in-house, and developed in collaboration with our IT department, we have continued to expand our cluster infrastructure, with the addition of a GPU partition for artificial intelligence (AI) analyses. Thanks to the Excelencia Severo Ochoa accreditation that VHIO received in 2021 as a Severo Ochoa Center of Excellence (2022-2026), and the support we receive from CRIS contra el cancer - the CRIS Cancer Foundation, we will continue to develop this infrastructure in 2026.

Our Bioinformatics Unit is a member of the Spanish translational bioinformatics network, TransBioNet, which is coordinated by the Spanish National Bioinformatics Institute (INB) and works in association with the European Life Science Infrastructure for Biological Information (ELIXIR). We also represent VHIO in various consortia and taskforces.

**Figure:** Word cloud showing analysis types performed in the unit during 2025, sized by frequency.

Expand and maintain scalable computational infrastructure, including GPU-enabled environments, to support advanced omics and AI-driven analyses.
Implement and optimize state-of-the-art bioinformatic pipelines for multi-omics data processing, integration, visualization, and interpretation, including public dataset reuse.
Develop integrative computational models and machine learning approaches to support biomarker discovery and precision oncology.
Strengthen institutional collaboration by promoting advanced computational methods across VHIO research programs.
Consolidate and mentor a highly skilled bioinformatics team while coordinating an internal knowledge-sharing network (e.g., Journal Club) to optimize expertise and resources.
Advance harmonized, FAIR-compliant data management practices across VHIO omics workflows.

Collaboration across 25 VHIO groups, contributing to 58 translational projects in 2025, spanning genomics, transcriptomics, metagenomics, and single-cell analyses.
Expansion of VHIO’s computational infrastructure, including new cluster nodes and GPU capacity to enable AI-based analyses, with workflows managed via Slurm, Docker, and Nextflow.
Implementation of standardized bioinformatic pipelines, supporting end-to-end omics analysis from raw sequencing data to advanced visualization.
Institution-wide data management assessment, conducted jointly with DERU, to map procedures and define improvements in research data lifecycle governance.
Active participation in national and international networks and scientific conferences, including TransBioNet/INB-ELIXIR and poster presentations at EuroBioC2025 and EMBL Cancer Genomics 2025.
Recruitment, mentoring, and training of specialized bioinformaticians, reinforcing institutional capacity in translational cancer research.

Full list of publications 2025

Incorporate AI-LLM models in the cluster to improve programming and AI modelling
Support the continuity of the Severo Ochoa Digital Oncology Unit (SOUND), together with other research groups and support units.
Manage the bioinformaticians network at VHIO and define a standard procedure to compute omics data analysis on the computational cluster.
Organize new internal courses on standard bioinformatic tasks such as functional enrichment analysis or extraction and visualization of public cancer repositories.
Provide bioinformatics support and guidance to VHIO’s research groups to help resolve any challenges raised during internal meetings or by our task forces (e.g. sequencing-based liquid biopsy analysis).
Assist VHIO's research groups in their data management practices and foster a collaborative journey toward open data sharing. In this context, one of the objectives of the cross-functional Data Management Group that we are part of, is to develop a protocol for data sharing through the process of publishing research papers.

Paper Pick 2025

Giuntini F, González-Larreategui Í, Herencia-Ropero A, Casacuberta-Serra S, Zacarías-Fluck MF, Arnal M, Pedretti F, Martínez-Martín S, Thabussot H, Cano VC, Grueso J, Foradada L, Serrano E, López-Estévez S, Rodriguez O, Guzman M, Rodriguez-Hernandez A, Brasó-Maristany F, Llop-Guevara A, Balmaña J, Nonell L, Prat A, Serra V, Beaulieu ME, Whitfield JR, Massó-Vallés D, Soucek L. MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. Cell Rep. 2025 Dec 23;44(12):116604.
Lloret-Llinares M, Carvajal-López P, Downing T, Gogol M, Ho Sui S, Nonell L, Paladin L, Reid AJ, Pomann GM, Brooksbank C. Competencies for bioinformatics core facility scientists: extension of the ISCB competency framework for bioinformatics. Bioinform Adv. 2025 Sep 16;5(1):vbaf206.

Giuntini F, González-Larreategui Í, Herencia-Ropero A, Casacuberta-Serra S, Zacarías-Fluck MF, Arnal M, Pedretti F, Martínez-Martín S, Thabussot H, Cano VC, Grueso J, Foradada L, Serrano E, López-Estévez S, Rodriguez O, Guzman M, Rodriguez-Hernandez A, Brasó-Maristany F, Llop-Guevara A, Balmaña J, Nonell L, Prat A, Serra V, Beaulieu ME, Whitfield JR, Massó-Vallés D, Soucek L. MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. Cell Rep. 2025 Dec 23;44(12):116604.
Lloret-Llinares M, Carvajal-López P, Downing T, Gogol M, Ho Sui S, Nonell L, Paladin L, Reid AJ, Pomann GM, Brooksbank C. Competencies for bioinformatics core facility scientists: extension of the ISCB competency framework for bioinformatics. Bioinform Adv. 2025 Sep 16;5(1):vbaf206.
Hernández-Muñoz I, Cuervas I, Prada E, Pulecio J, Gimeno R, Andrades E, Gómez-González S, Berenguer-Molins P, Acedo-Terrades A, Perera-Bel J, Bódalo-Torruella M, Nonell L, Pérez E, Grases D, Mata C, Yélamos J, Richaud-Patin Y, Vidal E, Cuartero Y, Le Dily F, Suñol M, Manzanares A, Raya A, Mora J. EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma. Nat Commun. 2025 Oct 24;16(1):9427.
Pedretti F, Abdalfttah M, Pellegrino B, Mateo F, Martínez-Sanz P, Herencia-Ropero A, Òdena A, Clavell-Revelles P, Casali G, Domènech H, Monserrat L, Papić D, Mas Malavila A, Pascual-Reguant A, Eixarch H, Guzmán M, Rodríguez O, Grueso J, Simonetti S, Fasani R, Nuciforo P, Espejo C, Florian S, Pujana MÁ, Nonell L, Seoane J, Valge-Archer V, O'Connor MJ, Nieto JC, Heyn H, Balmaña J, Llop-Guevara A, Serra V. Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer. Cancer Res. 2025 May 15;85(10):1888-1908.5: Acedo-Terrades A, Perera-Bel J, Nonell L. The importance of data transformation in RNA-Seq preprocessing for bladder cancer subtyping. BMC Res Notes. 2025 Feb 10;18(1):61.
Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937. a

Data Science Program

Oncology Data Science (ODysSey) Group

The ODysSey Group at VHIO promotes biomedical research by integrating cancer multi-omics data with clinical outcomes from oncology patients treated at the Vall d’Hebron University Hospital (HUVH). As experts in disease ontology and cancer semantics, we extract and process clinical data elements from electronic medical records. By using common data models, we standardize the format and content of observational healthcare data, harmonizing disparate coding systems with minimal information loss.

Our group designs and maintains comprehensive clinical-molecular repositories and custom data management solutions that empower researchers to conduct correlative analyses for hypothesis generation and biomarker validation, from genomics to computational pathology and radiology. Our team also assists investigators in identifying eligible patients for translational studies, clinical data collection through electronic case report forms, data processing and quality assessment. Working side by side with VHIO’s Statistics Unit, we collaborate in the design, analysis and interpretation of study results. Together with the Data Engineering for Research Unit, we deploy informatics tools to explore and visualize multi-omics data for research purposes and maintain web applications in the field of precision oncology care and clinical trial matching.

We actively participate in international real-world data analyses projects, foster collaborative research in computational oncology, and bridge connections among cancer researchers working on predictive and prognostic modeling, cancer driver identification, molecular subtyping, and tumor actionability.

**Figure:** VHIO’s Oncology Data Science (ODysSey) Group Workflow.

Facilitate high-quality clinical-molecular correlative studies and investigator-initiated trials (IITs) at VHIO:

Develop and maintain clinical-molecular databases, data management solutions, and decision-support systems as resources for clinicians, molecular pathologists, radiologists and translational researchers.
Provide guidance to medical oncologists and cancer biologists during the design and interpretation of clinical trials and biomarker correlative studies, as well as the development and validation of omics-based tests that have a direct clinical application.
We act as a key partner in the development of ad-hoc, customized electronic research data capture solutions tailored to the specific requirements of each study protocol. Additionally, we adopt standardized ontologies to accurately code specific terminology related to medical events.

Foster the adoption of common data models for real-world outcomes and translational research:

Promote reproducibility of research findings across different institutions by using open-source data processing and analytical tools.
Facilitate efficient study design and execution of analyses on patient-level observational data.

Promote evidence-based precision cancer care and clinical trial recruitment:

Advocate for the clinical adoption of the Molecular Tumor Board Portal (MTBP, https://mtbp.org) and Cancer Genome Interpreter (CGI, https://www.cancergenomeinterpreter.org) as decision support systems for the correct interpretation of genomic data and selection of the most appropriate targeted treatment. These portals leverage a variety of state-of-the-art tools to interpret the biological and clinical significance of tumor and germline alterations.
Integrate the OncoTrialsTrack platform (https://oncotrialstrack.vhio.net) with genomic reports that empower healthcare providers in the difficult and time-consuming task of finding the most suitable clinical trial for cancer patients based on molecular data.

Collaborative research on Big Data, Real-World Data and Digital Oncology:

Strengthen interactions among computational oncology scientists and preclinical-clinical researchers to promote the adoption of artificial intelligence solutions.
Foster digital oncology with the development of technological solutions to monitor, process and integrate different data at the individual and population levels to help address issues in health systems and the challenges faced by patients and clinicians.

We have provided support to VHIO investigators in biomarker discovery and validation. This has resulted in several impactful publications within our field as well as oral presentations at some of the most prestigious oncology conferences.
As the number of investigator-initiated studies increases at VHIO, we have become an essential data management partner, providing professional assistance in electronic data capture and expert medical advice in multiple clinical trials.
Widespread adoption of Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) to enable high quality and high relevance real-world outcomes and translational research
We have successfully delivered integrated analyses of multi-omics, from multi-centric real-world data cohorts in different molecular stratification projects sponsored by the European Commission, including COLOSSUS in colorectal cancer, and LEGACy in gastric cancer.
Our group is an active member of AACR’s Genomics Evidence Neoplasia Information Exchange (GENIE) project, and other international data sharing initiatives such as EUCANCan, that catalyze precision oncology through the development of regulatory-grade registries aggregating and linking cancer genomics data with clinical outcomes from tens of thousands of cancer patients treated at the participating institutions.
We have conducted several educational activities in the field of precision medicine field including Molecular Tumour Board meetings and specialized workshops to train investigators on how to explore public web resources with clinical-genomics data.

Full list of publications 2025

Programmatic clinical data collection and integration of artificial intelligence (language models) in the curation and qualification process.
Leadership in projects with federated learning, distributed network analysis, and synthetic data generation, allowing researchers to collaborate while safeguarding patient privacy and trust in data science.
Expand the partnership with the Clinical Research Support Unit (CRSU) at VHIO in the design and implementation of investigator-initiated clinical trials and registries, giving support in electronic data capture and statistical analyses.
Collaborate closely with our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Cancer Genomics, Molecular Oncology and Radiomics Groups to accelerate research and the implementation of cutting-edge data science models and technology platforms in the healthcare domain for the personalization of patient care at VHIO.
Cross-training and education in computational oncology, and the development of web-mobile applications for investigators, care providers and patients.

Paper Pick 2025

Dienstmann R, Ruiz-García E, Alsina M, Ruiz-Pace F, Groen-van Schooten TS, Martínez-Ciarpaglini C, Fernández-Figueroa EA, Herrera-Goepfert R, Díaz-Romero C, Lino-Silva L, Hernandez-Guerrero AI, Valdez-Reyes NM, León-Takahashi A, Falcón-Martínez JC, Pouw RE, Romero S, Villagrasa R, Cabeza-Segura M, Alarcón-Molero L, Jimenez-Martí E, Miralles A, Boggino H, Gauna C, Pereira R, Lezcano H, Cantero D, Vivancos A, Matito J, Martin A, Gómez M, Castillo E, Vila M, Ferreira RM, Barros R, Santos-Antunes J, Mendes-Rocha M, Costa A, Riquelme E, Roa JC, Latorre G, Freile B, Caro L, Esteso F, O'Connor J, Riquelme A, Owen G, Garrido M, Diez-García M, Figueiredo C, Caballero C, Lordick F, Farrés J, Derks S, Carneiro F, Cervantes A, Fleitas T. Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. ESMO Open. 2025 Mar;10(3):104482.
Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO Open. 2025 Nov;10(11):105888.

Projects

SYNTHIA: Synthetic Data Generation Framework For Integrated Validation Of Use Cases And AI Healthcare Applications.
EU-CIP: European Knowledge Hub and Policy Testbed for Critical Infrastructure Protection.
ROSALIND: Analysing and solving exceptional long-term survival in patients with poor prognosis solid tumors.
American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) project.
CGI-Clinics: Cancer Genomics Interpreter, a community-driven project that aims to improve precision medicine in oncology by optimizing genomic data interpretation.
PORTRAIT-TNBC: integrative multi-omics platform to identify predictive biomarkers of response to chemotherapy plus immunotherapy in early-stage triple negative breast cancer.
PragmaTIL: Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors.
Cancer Core Europe (CCE) DART: Building Data Rich Clinical Trials.
Cancer Core Europe (CCE) Consortium’s Basket of Baskets (BoB) clinical trial.

Dienstmann R, Ruiz-García E, Alsina M, Ruiz-Pace F, Groen-van Schooten TS, Martínez-Ciarpaglini C, Fernández-Figueroa EA, Herrera-Goepfert R, Díaz-Romero C, Lino-Silva L, Hernandez-Guerrero AI, Valdez-Reyes NM, León-Takahashi A, Falcón-Martínez JC, Pouw RE, Romero S, Villagrasa R, Cabeza-Segura M, Alarcón-Molero L, Jimenez-Martí E, Miralles A, Boggino H, Gauna C, Pereira R, Lezcano H, Cantero D, Vivancos A, Matito J, Martin A, Gómez M, Castillo E, Vila M, Ferreira RM, Barros R, Santos-Antunes J, Mendes-Rocha M, Costa A, Riquelme E, Roa JC, Latorre G, Freile B, Caro L, Esteso F, O'Connor J, Riquelme A, Owen G, Garrido M, Diez-García M, Figueiredo C, Caballero C, Lordick F, Farrés J, Derks S, Carneiro F, Cervantes A, Fleitas T. Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project. ESMO Open. 2025 Mar;10(3):104482.
Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO Open. 2025 Nov;10(11):105888.
Balaguer-Montero M, Marcos Morales A, Ligero M, Zatse C, Leiva D, Atlagich LM, Staikoglou N, Viaplana C, Monreal C, Mateo J, Hernando J, García-Álvarez A, Salvà F, Capdevila J, Elez E, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Rep Med. 2025 Apr 15;6(4):102032.
Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes ÁM, Alvarez-Escola C, Lecumberri B, González García A, K Flores S, Esquivel E, Ding Y, Peitzsch M, Robles-Guirado JÁ, Regojo Zapata RM, Pozo-Kreilinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Garrido-Lestache Rodríguez-Monte ME, Del Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, A Pereira MA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Llorente Pendás JL, Rueda Soriano J, Buendía Fuentes F, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opotowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirà L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA. Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer Discov. 2025 May 2;15(5):1037-1062.
Westphalen CB, Boscolo Bielo L, Aftimos P, Beltran H, Benary M, Chakravarty D, Collienne M, Dienstmann R, El Helali A, Gainor J, Horak P, Le Tourneau C, Marchiò C, Massard C, Meric-Bernstam F, Pauli C, Pruneri G, Roitberg F, Russnes HEG, Solit DB, Starling N, Subbiah V, Tamborero D, Tarazona N, Turnbull C, van de Haar J, André F, Mateo J, Curigliano G. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Ann Oncol. 2025 Jun;36(6):614-625.
Martínez-Ciarpaglini C, Barros R, Caballero C, Boggino H, Alarcón-Molero L, Peleteiro B, Ruiz-García E, Fernandez-Figueroa E, Herrera-Goepfert R, Díaz-Romero C, Ferreira R, Groen-van Schooten TS, Gauna C, Pereira R, Cantero D, Lezcano H, Esteso F, O Connor J, Riquelme A, Owen GI, Garrido M, Roa JC, Ruiz-Pace F, Vivancos A, Diez-García M, Alsina M, Matito J, Martin A, Gómez M, Castillo E, Vila M, Santos-Antunes J, Costa A, Lordick F, Farrés J, Palomar-De Lucas B, Cabeza-Segura M, Villagrasa R, Jimenez-Martí E, Miralles-Marco A, Dienstmann R, Derks S, Figueiredo C, Cervantes A, Carneiro F, Fleitas-Kanonnikoff T. Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Gastric Cancer. 2025 Mar;28(2):160-173.
Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, Dienstmann R, Tan TJY, Park WY, Abu Rasheed HM, Siu LL, Ma B, Ortiz-López R, Van den Bulcke M, Taucher SC, Ferris A, Starling N, Malapelle U, Longshore J, Saldaña HAB, Subbiah V. Precision Oncology: A Global Perspective on Implementation and Policy Development. JCO Glob Oncol. 2025 Jan;11:e2400416.
Uyar GC, Mirallas O, Başkurt K, Martin-Cullell B, Yeşilbaş E, Recuero-Borau J, Kaya S, Garcés VN, Yücel SE, Vega Cano KS, Gómez-Puerto D, Gómez AP, Salva de Torres C, Çakmak Öksüzoğlu ÖB, Serradell S, Dienstmann R, Sütcüoğlu O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Reg Health Eur. 2025 May 8;54:101317.
Barragan-Carillo R, Asirwa FC, Dienstmann R, Pendhakar D, Ruiz-Garcia E. Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473930.
Catani G, Morchón-Araujo D, Mirallas O, Sánchez-Pérez V, Nuciforo P, Villacampa G, Dienstmann R, Vivancos A, Garralda E, Hernando-Calvo A. Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies. Front Immunol. 2025 Oct 22;16:1664443.
Òdena A, Monserrat L, Brasó-Maristany F, García-Galea E, Casals E, Molina C, Herencia-Ropero A, Pedretti F, Domènech H, Guzmán M, Rodríguez O, Grueso J, Esteve-Codina A, Dienstmann R, Chandarlapaty S, Fan PD, Suto F, Oliveira M, Prat A, Serra V. Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts. NPJ Precis Oncol. 2025 Nov 21;9(1):393.
Oliveira LJC, Mano MS, Barrios C, Dienstmann R. The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6. Breast Cancer Res Treat. 2025 Nov 21;215(1):5.

Clinical Trials

A Phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected Tumor-infiltrating Lymphocytes (TILs) therapy in advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors.
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations.
A phase Ib study with a safety lead-in cohort and expansion phase, of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer.
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB).
Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors: the SERPENTINE clinical trial.
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy.
Multi-target approach including anti-angiogenic agent to overcome treatment resistance in BRAF mutant metastatic colorectal setting. BRAVE.
TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study.
Phase I, first-in human, open-label, dose escalation and cohort expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and antitumour activity of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphoma.
Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment (STROBE).
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer.
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients with Advanced High-Grade Osteosarcoma.
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CARTECH2Me T Cells in Patients with Selected Advanced Cancers.
A Phase 2, Single-Arm study of encorafenib plus cetuximab as rechallenge treatment of BRAF V600E-mutant metastatic colorectal cancer patients after previous therapy with BRAF inhibitors-based combinations: the RefIsh trial.
A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study.

Data Science Program

Statistics Unit

VHIO’s Statistics Unit implements innovative biostatistical methodologies to optimize study design, data analysis and interpretation to enhance clinical and preclinical research. Collaborating with research groups across multiple clinical trials and observational studies, we participate in various stages of research from experimental design through to data analysis and visualization and ultimately publication. Areas of focus include sample size calculation, statistical design of clinical trials, multi-state modelling, survival analyses, cost-utility analysis, and systematic reviews and meta-analyses.

Our Unit facilitates the design and initiation of VHIO investigator-initiated studies as well as new adaptive phase I/II clinical trial designs. We work closely with researchers on the design and publication of results from various VHIO-led clinical studies as well as validating the prognostic value of new tests and cancer biomarkers. In addition, we optimize real-world data to generate new insights beyond the context of clinical trials.

Our team participates in several different European and national projects aimed at developing and implementing novel statistical designs. We also work to enhance dose-escalation study designs to optimize dose selection in oncology drug development. Furthermore, we continue to evaluate the potential of synthetic control arms to compare the effectiveness of single-arm trials.

**Figure:** Main focus areas of VHIO’s Statistics Unit.

Statistical design in phase I, II and III trials to accelerate efficacy and safety analyses of novel anticancer therapies.
Construct prognostic and predictive models for the validation of new cancer biomarkers.
Conduct systematic reviews and meta-analyses to respond to important questions in cancer research.
Perform multi-state modelling and carry out survival analyses and competitive risk assessment.
Implementation of cost-effectiveness and cost-utility analyses to better integrate efficacy outcomes, quality of life, and economic costs.
Enhance the efficacy of synthetic controls as comparative groups in single-arm trials.
Establish and manage an optimal infrastructure for automated data processing, statistical analyses and reporting of results from preclinical research projects performed at VHIO.

Individual patient-level meta-analysis evaluating the association between HER2DX and survival outcomes in early HER2-positive breast cancer, published in The Lancet Oncology.
Statistical analysis and publication support for VHIO-sponsored clinical trials.
Implementation of health economic models to evaluate the cost-utility of biomarker-guided strategies.
Evaluation of the efficacy of immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer, published in the European Journal of Cancer.

Full list of publications 2025

Implement model-based designs in VHIO-sponsored phase I clinical trials.
Utilize real-world data to emulate clinical trials and quantify treatment benefits beyond the context of clinical trials.
Create automated analysis code to reduce analysis time and accelerate in-house research.
Integrate cost-effectiveness and cost-utility analyses in the design of future VHIO-sponsored clinical trials.
Implement an AI-powered tool to streamline the collection of published data and enhance the quality of systematic reviews.

Paper Pick 2025

Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 2025 Aug;26(8):1100-1112.
Villacampa G, Llop-Guevara A, Filmann N, Herencia-Ropero A, Fasching PA, Karn T, Marmé F, Klare P, Müller V, Stefek A, Schem C, Uleer C, Fehm T, Doering G, Stickeler E, van Mackelenbergh M, Felder B, Nekljudova V, Balmaña J, Denkert C, Loibl S, Serra V. RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial. Clin Cancer Res. 2025 Mar 3;31(5):808-814.
Villacampa G, Eminowicz G, Navarro V, Carità L, García-Illescas D, Oaknin A, Pérez-Fidalgo JA. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Eur J Cancer. 2025 May 2;220:115329.
Iacoboni G, Rejeski K, Navarro V, van Meerten T, Rampotas A, Martín-López AÁ, Bastos M, Benzaquén A, Reguera-Ortega JL, Carpio C, Roddie C, López-Corral L, Delgado-Serrano J, Landwehr M, Stock S, Silva de Tena P, Abrisqueta P, de Boer J, Martin Garcia-Sancho A, Hernani R, Kwon M, Subklewe M, O'Reilly M, Barba P. Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Leukemia. 2025 May;39(5):1196-1205.

Projects

Programa Integral de Inmunoterapia e Inmunología del Cáncer (CAIMI). Funded by BBVA, this program focuses on strategic lines aimed at evaluating how to utilize the immune system to advance cancer immunotherapies.
Cancer Core Europe (CCE). Founded in 2014, this consortium comprises seven leading European comprehensive cancer centers, including VHIO, to accelerate the development of innovative cancer therapies through close collaboration in translational and clinical research.
The EU-funded CCE Building Data Rich Clinical Trials (CCE_DART) is an innovative project dedicated to deliver novel methods for the design and implementation of newer, more efficient and effective clinical trials in oncology.
FIS project: PRiSma II: Estratificación del riesgo de cáncer de mama/ovario mediante incorporación del polygenic risk score. Validación en portadoras, cohorte prospectiva, y viabilidad de la secuenciación de genoma. PI23/01047.

Oliveira M, Ciruelos E, Villacampa G, Morales S, Salvador Bofill J, Quiroga V, Gavilá J, Cortegoso A, Vega E, Henao F, Servitja S, Tolosa P, Chillara S, Bergamino M, Salvador F, Paes Dias M, Ferrero-Cafiero JM, Gonzalez Farre X, Pascual T, Saura C. Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trial. Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-2298. Epub ahead of print. PMID: 41324568.
Ciruelos E, Pascual T, Villacampa G, Pernas S, Sanchez Bayona R, Ponce J, Cantos B, Escrivá-de-Romaní S, Perelló A, Sanfeliu E, Galvan P, Montaño A, Martínez E, Lopez A, Mele M, de la Haba J, Cortés J, Mulero-Sánchez A, Ferrero-Cafiero JM, Oliveira M, Villanueva L, Gonzalez X, Villagrasa P, Prat A. Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial. Clin Cancer Res. 2025 Dec 3. doi: 10.1158/1078-0432.CCR-25-2882. Epub ahead of print. PMID: 41335375.
Escudero A, Bellet M, Saura C, Aguilera A, Papakonstantinou A, Tolosa P, García-Sáenz JÁ, Moreno F, López de Sá A, Schettini F, Seguí E, Gonzalez-Rodriguez M, Navarro V, Ferrero-Cafiero JM, González X, Hernando C, Matikas A, Prat A, Oliveira M, Pascual T, Villacampa G. Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis. Cancer Treat Rev. 2026 Jan;142:103063. doi: 10.1016/j.ctrv.2025.103063. Epub 2025 Dec 3. PMID: 41385990.
Rojas L, Villacampa G, Tan DSW, Arrieta O, Zuluaga J, Cardona AF. A world map of air pollution and EGFR-mutant prevalence. Clin Transl Oncol. 2026 Feb;28(2):719-725. doi: 10.1007/s12094-025-04039-0. Epub 2025 Aug 28. PMID: 40877732.
Seguí E, Brasó-Maristany F, Pascual T, Sanfeliu E, Victoria I, Saura C, Hierro C, López-González A, Izarzugaza Y, Ciruelos E, Gavilá J, Racca F, Cejalvo JM, Amillano K, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Conte B, Walbaum B, Indacochea A, Castillo O, Blasco P, Pardo F, Aguirre Á, Sirenko V, González X, Galván P, Vivancos A, Ferrero-Cafiero JM, Mulero-Sánchez A, Salvador F, Villacampa G, Mesía R, Cervantes A, Prat A, Tabernero J. Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial. ESMO Open. 2025 Oct;10(10):105838. doi: 10.1016/j.esmoop.2025.105838. Epub 2025 Sep 30. PMID: 41033278; PMCID: PMC12514499.
Rescigno P, Fenor de la Maza MD, Tovey H, Villacampa G, Cafferty F, Burnett S, Stiles M, Gurel B, Tunariu N, Carreira S, Figueiredo I, Beije N, Flohr P, Hall E, Hill A, Mahmud M, Perna C, Sarvadikar A, Sharp A, Abramovich K, Aversa C, Bertran C, Bianchini D, Carmichael J, Chandran K, Crespo M, Cross E, Curcean A, Ferreira A, Grochot R, Guo C, Hamilton L, Harden L, Hunt J, Longoria O, Martos L, Miranda S, Riisnaes R, Vadgama S, Westaby D, Wilkinson J, Yap C, de Bono JS. PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes. Eur Urol Oncol. 2025 Aug;8(4):1059-1069. doi: 10.1016/j.euo.2025.04.025. Epub 2025 Jun 25. PMID: 40571546.
Catani G, Morchón-Araujo D, Mirallas O, Sánchez-Pérez V, Nuciforo P, Villacampa G, Dienstmann R, Vivancos A, Garralda E, Hernando-Calvo A. Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies. Front Immunol. 2025 Oct 22;16:1664443. doi: 10.3389/fimmu.2025.1664443. PMID: 41200168; PMCID: PMC12586187.
Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, Kurosaki A, Minobe S, Villacampa G, Oaknin A, Okamoto A. Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. J Gynecol Oncol. 2025 Nov;36(6):e116. doi: 10.3802/jgo.2025.36.e116. Epub 2025 May 19. PMID: 40968753; PMCID: PMC12636115.
Angelats L, Paré L, Rubio-Perez C, Sanfeliu E, González A, Seguí E, Villacampa G, Marín-Aguilera M, Pernas S, Conte B, Albarrán-Fernández V, Martínez-Sáez O, Aguirre Á, Galván P, Fernandez-Martinez A, Cobo S, Rey M, Martínez-Romero A, Walbaum B, Schettini F, Vidal M, Buckingham W, Muñoz M, Adamo B, Agrawal Y, Guedan S, Pascual T, Agudo J, Grzelak M, Borcherding N, Heyn H, Vivancos A, Parker JS, Villagrasa P, Perou CM, Prat A, Brasó-Maristany F. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open. 2025 Jan;10(1):104109. doi: 10.1016/j.esmoop.2024.104109. Epub 2025 Jan 6. PMID: 39765189; PMCID: PMC11758579.
Nozawa K, Sawaki M, Uemura Y, Tsuneizumi M, Takano T, Gondo N, Hara F, Harao M, Toyama T, Taira N, Vivancos A, Perou CM, Sanfeliu E, Brasó-Maristany F, Parker JS, Buckingham W, Paré L, Villacampa G, Marín-Aguilera M, Villagrasa P, Prat A, Iwata H. HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. Nat Commun. 2025 Nov 4;16(1):9585. doi: 10.1038/s41467-025-65599-x. PMID: 41188218; PMCID: PMC12586486.
Martín-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Villacampa G, Galvao V, Lostes J, Muñoz-Couselo E, Rotxés M, Villalobos X, Muñoz S, Haanen JBAG, Svane IM, Piulats JM, Martin-Liberal J, Gros A, Coukos G, Garralda E. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2025 Aug;36(8):909-919. doi: 10.1016/j.annonc.2025.04.001. Epub 2025 Apr 8. PMID: 40210086.
Pascual T, Villacampa G, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Villanueva L, Gonzalez-Rodriguez M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Ferrero-Cafiero JM, González-Farré X, Villagrasa P, Prat A, Ciruelos E. Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. ESMO Open. 2025 Sep;10(9):105572. doi: 10.1016/j.esmoop.2025.105572. Epub 2025 Sep 1. PMID: 40896880; PMCID: PMC12424417.
Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A. A Randomized clinical trial evaluating the impact on survival and quality of life of ¹⁷⁷Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3. PMID: 40186126; PMCID: PMC11971812.
López-Fernández A, Duran-Lozano L, Villacampa G, Pardo M, Pérez E, Darder E, Vallmajó A, Alfonso R, Cruellas M, Roqué A, Cartró M, Bareas A, Carrasco E, Rezqallah A, Jimenez-Macedo AR, Torres-Esquius S, Torres M, Lopez C, Espinosa M, Teulé A, Munté E, Tuset N, Diez O, Feliubadaló L, Lázaro C, Llort G, Carver T, Ficorella L, Mavaddat N, Mercadé A, Antoniou AC, Brunet J, Ramon Y Cajal T, Balmaña J. A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. J Natl Cancer Inst. 2025 Aug 1;117(8):1593-1604. doi: 10.1093/jnci/djaf067. PMID: 40170233; PMCID: PMC12342814.
Sánchez-Bayona R, Martínez-Sáez O, Romero-Romero D, Seguí E, Carcelero E, Tolosa P, Soberino J, Alva M, Pascual T, Lema L, Garcia-Fructuoso I, Cobos-Fernandez MA, Rey M, Manso L, Aguirre A, Madariaga A, Sirenko V, González-Deza C, Blasco P, Mayhua A, Castillo O, Galván P, Sanfeliu E, Villacampa G, Buckingham W, Marín-Aguilera M, Paré L, Villagrasa P, Perou CM, Maues J, Brasó-Maristany F, Ciruelos E, Prat A. HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab. NPJ Breast Cancer. 2025 Apr 25;11(1):37. doi: 10.1038/s41523-025-00753-8. PMID: 40280938; PMCID: PMC12032064.
Stecklein SR, Martín M, Villacampa G, Del Monte-Millan M, Yoder R, Pathak H, Cobo S, Brasó-Maristany F, Álvarez EL, Echavarría I, Bueno-Muiño C, Jerez Y, Cebollero M, Bueno O, García-Saenz JÁ, Moreno F, Gómez HL, Massarrah T, Herrero B, Paré L, Marín-Aguilera M, Buckingham W, López-Tarruella S, Villagrasa P, Godwin AK, Salgado R, Prat A, Sharma P. Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer. J Natl Cancer Inst. 2025 Jul 2:djaf162. doi: 10.1093/jnci/djaf162. Epub ahead of print. PMID: 40600921.
Martín M, Stecklein SR, Gluz O, Villacampa G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F, Álvarez EL, Echavarría I, Conte B, Kuemmel S, Bueno-Muiño C, Jerez Y, Kates R, Cebollero M, Kolberg-Liedtke C, Bueno O, García-Saenz JÁ, Moreno F, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstleins R, Graeser M, Zu Eulenburg C, Kreipe HH, Gómez H, Massarrah T, Herrero B, Paré L, Bohn U, López-Tarruella S, Vivancos A, Sanfeliu E, Parker JS, Perou CM, Villagrasa P, Prat A, Sharma P, Harbeck N. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Ann Oncol. 2025 Feb;36(2):158-171. doi: 10.1016/j.annonc.2024.10.012. Epub 2024 Oct 16. PMID: 39419289.
Villacampa G, Eminowicz G, Navarro V, Carità L, García-Illescas D, Oaknin A, Pérez-Fidalgo JA. Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis. Eur J Cancer. 2025 May 2;220:115329. doi: 10.1016/j.ejca.2025.115329. Epub 2025 Feb 26. PMID: 40031426.
Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis. Lancet Oncol. 2025 Aug;26(8):1100-1112. doi: 10.1016/S1470-2045(25)00276-1. Epub 2025 Jul 14. PMID: 40675165.
Bastos-Oreiro M, Iacoboni G, Garcés VN, Caballero AC, Martínez N, Delgado J, Balaguer A, Kwon M, Gonzalez de Villambrosia S, Hernani R, Jimenez-Ubieto A, Bailen R, Zaberio I, Martín García-Sancho A, Barba P. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Hemasphere. 2025 Feb 4;9(2):e70077. doi: 10.1002/hem3.70077. PMID: 39906687; PMCID: PMC11792173.
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, Matikas A. Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis. EClinicalMedicine. 2025 Feb 17;81:103116. doi: 10.1016/j.eclinm.2025.103116. PMID: 40034565; PMCID: PMC11875833.
Schettini F, Nucera S, Pascual T, Martínez-Sáez O, Sánchez-Bayona R, Conte B, Buono G, Lambertini M, Punie K, Cejalvo JM, Arpino G, Vigneri P, Generali D, Ciruelos E, Cortés J, Gennari A, Muñoz M, Vidal Losada MJ, Tolaney SM, Prat A, Villacampa G. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis. Cancer Treat Rev. 2025 Jan;132:102865. doi: 10.1016/j.ctrv.2024.102865. Epub 2024 Dec 19. PMID: 39709655.
Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, Berlin J, Boix O, Calvert M, Chan AW, Coschi CH, Evans TRJ, Garrett-Mayer E, Golub RM, Guo C, Hayward KS, Hopewell S, Isaacs JD, Ivy SP, Jaki T, Kholmanskikh O, Kightley A, Lee S, Liu R, Mander A, Marshall LV, Matcham J, Patel D, Peck R, Rantell KR, Richards DP, Rouhifard M, Seymour L, Tanaka Y, Weir CJ, de Bono J, Yap C. SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols. EClinicalMedicine. 2025 Jan 10;79:102988. doi: 10.1016/j.eclinm.2024.102988. PMID: 39877554; PMCID: PMC11773215.
Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E. Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Eur J Cancer. 2025 Feb 25;217:115219. doi: 10.1016/j.ejca.2024.115219. Epub 2025 Jan 3. PMID: 39779447.
Hidalgo-Gómez G, Tazón-Vega B, Palacio C, Saumell S, Martínez-Morgado N, Navarro V, Murillo L, Velasco P, Murciano T, Díaz de Heredia C, Bosch F, Armengol G, Ortega M. How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia. Ann Hematol. 2025 Apr;104(4):2387-2402. doi: 10.1007/s00277-024-06151-7. Epub 2025 Jan 23. PMID: 39843811; PMCID: PMC12052862.
Medina-Gil D, Palomo L, Navarro V, Lázaro G, Martín-Mur B, Hernández C, Castells O, Sánchez B, Muñoz-Torres PM, Pagès C, Pujadas G, Esteve-Codina A, Cabirta A, Ferrà C, Alcoceba M, Terol MJ, Andreu R, Martí M, Abrisqueta P, Bosch F, Crespo M. Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia. Haematologica. 2025 Aug 1;110(8):1758-1773. doi: 10.3324/haematol.2024.286663. Epub 2025 Mar 13. PMID: 40079085; PMCID: PMC12358782.
Serna Á, Navarro V, Iacoboni G, López L, Sancho JM, González-Barca E, López-García A, Córdoba R, Sáez A, Jiménez-Ubieto A, Ferrero A, García T, Sánchez Á, García C, Bosch M, Cabirta A, Jiménez M, Marín-Niebla A, Bosch F, Abrisqueta P. Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica. 2025 Jan 1;110(1):173-178. doi: 10.3324/haematol.2024.285219. PMID: 38988269; PMCID: PMC11694125.
Uyar GC, Mirallas O, Başkurt K, Martin-Cullell B, Yeşilbaş E, Recuero-Borau J, Kaya S, Garcés VN, Yücel SE, Vega Cano KS, Gómez-Puerto D, Gómez AP, Salva de Torres C, Çakmak Öksüzoğlu ÖB, Serradell S, Dienstmann R, Sütcüoğlu O. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Reg Health Eur. 2025 May 8;54:101317. doi: 10.1016/j.lanepe.2025.101317. PMID: 40672056; PMCID: PMC12266187.
Cruellas M, Papakonstantinou A, López-Fernández A, Castillo E, Matito J, Gómez M, Rezqallah A, Vega S, Navarro V, Torres M, Moles-Fernández A, Saura C, Vivancos A, Balmaña J, Oliveira M. Identifying germline pathogenic variants in breast cancer using tumor sequencing. Breast. 2025 Jun;81:104439. doi: 10.1016/j.breast.2025.104439. Epub 2025 Mar 12. PMID: 40090122; PMCID: PMC11952849.
Alsina M, Villacampa G, de Andrea C, Vivancos A, Ponz-Sarvise M, Arrazubi V, Jimenez-Fonseca P, Diez M, Sanz-Garcia E, Martínez E, Guardeño R, Calvo M, Bugés C, Longo F, Navarro V, García-Galea E, Gros A, Ochoa MC, Lopez-Janeiro A, Sanchez-Gregorio S, Herrero C, Labiano I, Vila-Casadesús M, López D, Alexandru R, Muñoz S, Tabernero J, Melero I. A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study. Clin Cancer Res. 2025 Jul 15;31(14):2890-2898. doi: 10.1158/1078-0432.CCR-25-0369. PMID: 40388549; PMCID: PMC12260514.
Iacoboni G, Rejeski K, Navarro V, van Meerten T, Rampotas A, Martín-López AÁ, Bastos M, Benzaquén A, Reguera-Ortega JL, Carpio C, Roddie C, López-Corral L, Delgado-Serrano J, Landwehr M, Stock S, Silva de Tena P, Abrisqueta P, de Boer J, Martin Garcia-Sancho A, Hernani R, Kwon M, Subklewe M, O'Reilly M, Barba P. Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Leukemia. 2025 May;39(5):1196-1205. doi: 10.1038/s41375-025-02582-x. Epub 2025 Apr 1. PMID: 40169762.
López-Fernández A, Pardo M, Pérez-Ballestero E, Darder E, Alfonso R, Torres-Esquius S, Navarro Garcés V, Ramón Y Cajal T, Brunet J, Balmaña J. Exploring communication preferences for disclosing breast cancer risk in women with a family history. J Genet Couns. 2025 Oct;34(5):e70114. doi: 10.1002/jgc4.70114. PMID: 40965181.
Schettini F, Nucera S, Pascual T, Martínez-Sáez O, Sánchez-Bayona R, Conte B, Buono G, Lambertini M, Punie K, Cejalvo JM, Arpino G, Vigneri P, Generali D, Ciruelos E, Cortés J, Gennari A, Muñoz M, Vidal Losada MJ, Tolaney SM, Prat A, Villacampa G. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis. Cancer Treat Rev. 2025 Jan;132:102865. doi: 10.1016/j.ctrv.2024.102865. Epub 2024 Dec 19. PMID: 39709655.
Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 Jun;34(6):543-552. doi: 10.1016/j.annonc.2023.02.016. Epub 2023 Mar 14. Erratum in: Ann Oncol. 2024 Oct;35(10):922. doi: 10.1016/j.annonc.2023.07.010. PMID: 36921693.
Serna Á, Navarro V, Jiménez M, Iraola-Truchuelo J, Bosch M, García C, Falcó A, Albasanz A, Ruiz-Camps I, Andrés C, Antón A, Esperalba J, Ferrero A, García T, Carpio C, Crespo M, Iacoboni G, Marín-Niebla A, Bosch F, Abrisqueta P. Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders. Blood Adv. 2025 Aug 26;9(16):4180-4189. doi: 10.1182/bloodadvances.2024015406. PMID: 40402079; PMCID: PMC12361758.
Torrent-Rodríguez A, Cascos E, Garcés VN, Pérez-López E, Baile-González M, Rodríguez CM, Cascón MJP, Luque M, Esquirol A, Calvo CM, Peña-Muñoz F, Fernando IH, Ormtegi IO, Marín AJS, Fernández-Luis S, Domínguez-García JJ, Fernández SV, Lorenzo JLL, de Sanmamed Girón MF, Pinedo LG, García-Maño L, González-Rodriguez AP, Torrado T, Filaferro S, Basalobre P, Ortí G, Rovira M, Chacón MJ, Salas MQ; GETH-TC. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers (Basel). 2025 Sep 26;17(19):3128. doi: 10.3390/cancers17193128. PMID: 41097656; PMCID: PMC12523613.

Laboratory Animal Service (LAS)